Wikipedia -WSS

Wikipedia

author：focus 2025-09-28 00:25:56 - browse：4

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： An interview with Robert F. Kennedy Jr. on vaccines

hotspot

WSS

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

RSV injection headlines need to be accurate for good uptake

Evacuations in place as 3 wildfires burn in eastern Washington state

ProMED sees offers of support, but its future remains unclear

Stop Congress from blocking public access to science

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Wikipedia

Wikipedia

explore

Novavax promises a turnaround & Lilly roils the obesity market

The biotech scorecard for Q4: 16 stock

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New definition of a human embryo proposed amid rapid advances

Trump demands the U.S. pay no more for drugs than other countries … again

6 solutions to address cancer drug shortages and others

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eye stem cell transplant could help restore vision in injured people

Peter Hotez and the public health issue of online harassment

Listen: Racing for gene therapy & a pioneering approval

knowledge

Medicare innovation center doesn’t save money, experts say

Beware the threat of staffing cuts at the CDC

What we owe ALS patients — and why one company fell short

IVG is promising — but it won’t replace IVF quite yet

Some top drug companies are starting to take action on climate

IVG is promising — but it won’t replace IVF quite yet

hotspot

focus

knowledge

focus